Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1290-1294

  Rowe, Jacob M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIMICROBIAL ACTIVITY; BONE MARROW HYPOPLASIA; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; FEVER; HUMAN; INFECTION; LEUKEMIA REMISSION; LUNG TOXICITY; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031811585     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516360     Document Type: Review

References (24)

1. Büchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991;78:1190-7.
2. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study by the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62.
3. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995;332:1678-83.
4. Link H, Wandt H, Schönrock-Nabulsi, et al. G-CSF (lenograstim) after chemotherapy for acute myeloid leukemia: a placebo controlled trial. Blood 1996;88(suppl 1):2654a.
5. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871-7.
6. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83: 2086-92.
7. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before,.during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8.
8. Godwin JE, Kopecky KJ, Head DR, et al. Double-blind, placebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1995; 86(suppl 1):434a.
9. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997 (in press).
10. Stone RN, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332: 1671-7.
11. Löwenberg B, Suciu S, Zittoun R, et al. GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). Blood 1995;86(suppl 1):433a.
12. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia. A randomized trial by the European Organization for Research and Treatment of Cancer and Leukemia Cooperative Group. J Clin Oncol 1996;14:2150-9.
13. Witz F, Harousseau JL, Sadoun A, et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematology Blood Transfusion 1997;40:852-6.
14. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675-85.
15. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996;14:1371-82.
16. Büchner T, Hiddemann W, Wörmann B, et al. Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 1997;24:124-31.
17. Terpstra W, Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997;11:315-27.
18. Rowe JM, Liesveld JL. Hematopoietic growth factors in acute leukemia. Leukemia 1997;11:328-41.
19. Bennett CL, Golub R, Waters TM, et al. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997;15:227-36.
20. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8.
21. Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989;7:1791-9.
22. Denzlinger C, Tetzloof W, Gerhartz HH, et al. Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers. Blood 1993;81:2007-13.
23. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15:19-29.
24. Kaushansky K, O'Hara PJ, Hart CE, et al. Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. Biochemistry 1987;26:4861-7.